-+ 0.00%
-+ 0.00%
-+ 0.00%

Haizheng Pharmaceutical (600267.SH) subsidiary obtained approval document approval for veterinary drug products

Zhitongcaijing·12/05/2025 08:49:02
Listen to the news

Zhitong Finance App News, Haizheng Pharmaceutical (600267.SH) issued an announcement. Recently, Yunnan Biopharmaceutical Co., Ltd. (“Yunnan Biology”), a wholly-owned subsidiary of Zhejiang Haizheng Animal Health Products Co., Ltd., the company's holding subsidiary, received approval number approval for Mycoplasma porcine pneumonia inactivated vaccine (GD0503 strain) veterinary drug product approved and issued by the Ministry of Agriculture and Rural Affairs of the People's Republic of China.

Mycoplasma porcine pneumonia inactivated vaccine (GD0503 strain) is suitable for preventing Mycoplasma porcine pneumonia (swine wheezing disease). Immunity develops 28 days after vaccination, and the immunization period is 6 months. This vaccine product is prepared by using the MD0503 strain of Mycoplasma porcine pneumoniae to inoculate MH medium, concentrate, purify, and inactivate the harvested culture, and then add an oil adjuvant.